Renal Denervation Shows Sustained Blood Pressure Reduction and Safety Over 24 Months in SPYRAL HTN-ON MED Trial
The SPYRAL HTN-ON MED trial demonstrates that renal denervation provides significant long-term reductions in both ambulatory and office systolic blood pressure with good safety, supporting its role in managing hypertension.